112 related articles for article (PubMed ID: 11104553)
21. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
22. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.
Masciari S; Van den Abbeele AD; Diller LR; Rastarhuyeva I; Yap J; Schneider K; Digianni L; Li FP; Fraumeni JF; Syngal S; Garber JE
JAMA; 2008 Mar; 299(11):1315-9. PubMed ID: 18349092
[TBL] [Abstract][Full Text] [Related]
23. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary.
Wang G; Wu Y; Zhang W; Li J; Wu P; Xie C
J Med Imaging Radiat Oncol; 2013 Feb; 57(1):65-71. PubMed ID: 23374557
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker.
Chang WC; Hung YC; Kao CH; Yen RF; Shen YY; Lin CC
Neoplasma; 2002; 49(5):329-33. PubMed ID: 12458332
[TBL] [Abstract][Full Text] [Related]
26. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
27. Ten-year prospective evaluation of whole-body cancer screening with multiple modalities including [
Nishizawa S; Kojima S; Okada H; Shinke T; Torizuka T; Teramukai S; Fukushima M
Ann Nucl Med; 2020 May; 34(5):358-368. PubMed ID: 32200511
[TBL] [Abstract][Full Text] [Related]
28. Increase of serum CA19-9 level without an evident lesion on conventional imaging is insufficient for justification of 18FDG-PET examination.
Inoue K; Okada K; Taki Y; Goto R; Kinomura S; Kaneta T; Fukuda H
Hepatogastroenterology; 2008; 55(81):46-9. PubMed ID: 18507076
[TBL] [Abstract][Full Text] [Related]
29. Primary colorectal cancers detected with PET.
Yasuda S; Takahashi W; Takagi S; Ide M; Shohtsu A
Jpn J Clin Oncol; 1998 Oct; 28(10):638-40. PubMed ID: 9839506
[TBL] [Abstract][Full Text] [Related]
30. Who wants cancer screening with PET? A contingent valuation survey in Japan.
Yasunaga H
Eur J Radiol; 2009 Apr; 70(1):190-4. PubMed ID: 18093777
[TBL] [Abstract][Full Text] [Related]
31. Cancer screening with whole-body 18F-fluorodeoxyglucose positron-emission tomography.
Yasuda S; Shohtsu A
Lancet; 1997 Dec 20-27; 350(9094):1819. PubMed ID: 9428255
[No Abstract] [Full Text] [Related]
32. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.
Lennon AM; Buchanan AH; Kinde I; Warren A; Honushefsky A; Cohain AT; Ledbetter DH; Sanfilippo F; Sheridan K; Rosica D; Adonizio CS; Hwang HJ; Lahouel K; Cohen JD; Douville C; Patel AA; Hagmann LN; Rolston DD; Malani N; Zhou S; Bettegowda C; Diehl DL; Urban B; Still CD; Kann L; Woods JI; Salvati ZM; Vadakara J; Leeming R; Bhattacharya P; Walter C; Parker A; Lengauer C; Klein A; Tomasetti C; Fishman EK; Hruban RH; Kinzler KW; Vogelstein B; Papadopoulos N
Science; 2020 Jul; 369(6499):. PubMed ID: 32345712
[TBL] [Abstract][Full Text] [Related]
33. The role of positron emission tomography in oncology and other whole-body applications.
Hawkins RA; Hoh C; Glaspy J; Choi Y; Dahlbom M; Rege S; Messa C; Nietszche E; Hoffman E; Seeger L
Semin Nucl Med; 1992 Oct; 22(4):268-84. PubMed ID: 1439872
[TBL] [Abstract][Full Text] [Related]
34. Positron emission tomography for tumour assessment.
Jones T; Tilsley DW; Wilson CB; Lammertsma AA; Brown G; Brady F; Price PM
NMR Biomed; 1992; 5(5):265-9. PubMed ID: 1449966
[TBL] [Abstract][Full Text] [Related]
35. [PET and Cancer Screening].
Yasuda S; Ide M
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2005 Jun; 61(6):759-65. PubMed ID: 15995603
[No Abstract] [Full Text] [Related]
36. [Positron emission tomography--PET].
Lind P
Wien Med Wochenschr; 2002; 152(11-12):254. PubMed ID: 12138650
[No Abstract] [Full Text] [Related]
37. [
Peng L; Liao Y; Zhou R; Zhong Y; Jiang H; Wang J; Fu Y; Xue L; Zhang X; Sun M; Feng G; Meng Z; Peng S; He X; Teng G; Gao X; Zhang H; Tian M
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3723-3734. PubMed ID: 37401938
[TBL] [Abstract][Full Text] [Related]
38. Extra-articular findings with FDG-PET/CT in rheumatoid arthritis patients: more harm than benefit.
Ulijn E; den Broeder AA; Boers N; Gotthardt M; Bouman CAM; Landewé R; den Broeder N; van Herwaarden N
Rheumatol Adv Pract; 2022; 6(1):rkac014. PubMed ID: 35311064
[TBL] [Abstract][Full Text] [Related]
39. Minicircles for a two-step blood biomarker and PET imaging early cancer detection strategy.
Robinson ER; Gowrishankar G; D'Souza AL; Kheirolomoom A; Haywood T; Hori SS; Chuang HY; Zeng Y; Tumbale SK; Aalipour A; Beinat C; Alam IS; Sathirachinda A; Kanada M; Paulmurugan R; Ferrara KW; Gambhir SS
J Control Release; 2021 Jul; 335():281-289. PubMed ID: 34029631
[TBL] [Abstract][Full Text] [Related]
40. Unintentional weight loss: what radiologists need to know and what clinicians want to know.
Rao S; Kikano EG; Smith DA; Guler E; Tirumani SH; Ramaiya NH
Abdom Radiol (NY); 2021 May; 46(5):2236-2250. PubMed ID: 33386448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
